Overview

Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease

Status:
Recruiting

Trial end date:
2021-03-31

Target enrollment:

Participant gender:

Summary

This is a multi-center, Phase 1b, randomized, double-blind, placebo-controlled parallel-group trial in adults with mild to moderate AD.

Phase:

Phase 1

Details

Lead Sponsor:

Cognition Therapeutics